Form 4: Incyte Director Jacqualyn Fouse Granted Over 11,700 Shares and Options as Part of Compensation

Incyte Corporation Director Jacqualyn A. Fouse was granted 2,518 restricted stock units and 9,216 non-qualified stock options on June 10, 2025, as part of her compensation, increasing her total beneficial ownership.

Summary

• Incyte Corporation Director Jacqualyn A. Fouse acquired 2,518 shares of common stock through a grant of restricted stock units (RSUs) on June 10, 2025.
• These RSUs vest in full on the first anniversary of the grant date (June 10, 2026), or earlier upon the date of the next regular annual meeting of the Company's stockholders or upon a change of control.
• The RSUs may be settled only for shares of common stock on a one-for-one basis.
• Following this transaction, Ms. Fouse beneficially owns 19,326 shares of common stock, which includes this grant and other previously reported holdings.
• Additionally, Ms. Fouse was granted 9,216 non-qualified stock options with an exercise price of $70.07 per share on June 10, 2025.
• These stock options vest in full on the first anniversary of the grant date (June 10, 2026), or earlier upon the date of the next regular annual meeting of the Company's stockholders or upon a change of control, and expire on June 9, 2035.
• After this transaction, Ms. Fouse beneficially owns 9,216 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is generally a positive signal, indicating alignment of interests and a standard practice for incentivizing long-term commitment. It does not, however, provide direct insight into operational performance or financial health beyond compensation structure.

Positives

• The grant of 2,518 restricted stock units and 9,216 non-qualified stock options to Director Jacqualyn A. Fouse aligns her interests with shareholders, as her compensation is tied to the company's future performance.
• The acquisition of equity by a director can signal confidence in the company's future prospects and long-term strategy.

Future Outlook

The vesting schedules for both the restricted stock units and stock options indicate a forward-looking incentive structure, tying the director's compensation to the company's performance over the next year or until a significant corporate event, such as the next annual meeting or a change of control.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industries where executive and director compensation often includes equity grants like restricted stock units and stock options to align leadership interests with long-term shareholder value creation. Such compensation structures are common across publicly traded companies in the sector.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and non-qualified stock options as part of director compensation is a common practice across the S&P 500 and particularly prevalent in the biotechnology and pharmaceutical sectors, where long-term incentives are crucial for retaining talent and aligning interests.
• Companies like Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) frequently utilize similar equity-based compensation plans for their directors and executives, often with vesting periods tied to continued service or performance milestones.
• The specific grant amounts are proportional to the director's role and the company's size, though direct comparisons without full compensation disclosures are difficult.

Related Party Transactions

• The grant of restricted stock units and stock options to a director constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• **Shareholders**: The equity grants align the director's interests with shareholders by tying a portion of her compensation to the company's stock performance, potentially encouraging decisions that enhance shareholder value.
• **Employees**: No direct impact on general employees is indicated by this filing.
• **Management**: The compensation structure for directors can influence the overall compensation philosophy for the broader management team.

Next Steps

• The 2,518 restricted stock units are expected to vest on the first anniversary of the grant date (June 10, 2026), or earlier upon the next regular annual meeting of Incyte's stockholders or a change of control.
• The 9,216 non-qualified stock options are expected to vest on the first anniversary of the grant date (June 10, 2026), or earlier upon the next regular annual meeting of Incyte's stockholders or a change of control.

Key Dates

Recommendation

Keywords

Incyte Corp, INCY, Form 4, SEC Filing, Insider Transaction, Stock Grant, Stock Options, Restricted Stock Units, Director Compensation, Equity Compensation, Beneficial Ownership, Pharmaceuticals, Biotechnology